Fair Value Calculator Fair Value Calculator
EN DE

DRA (DRA) Fair Value & Analysis

IN · Market cap ₹206M

D DRA DRA · BSE
Price₹18.81
Fair Value₹26.55
Upside+41.1%
Quality48/100
Watch DRA for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range ₹25.26 – ₹30.22

Fair value as of: Jul 5, 2026

From 24 valuation models · updated today

Share price −3.0% over the past month.

Price vs Fair Value (12 months)

₹27.00 ₹13.10 Fair Value ₹26.55 Jul 2025 Jul 2026

12‑month range ₹13.10 – ₹27.00 · fair‑value band ₹25.26 – ₹30.22 · the ₹18.81 price screens below the ₹26.55 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

DRA (DRA) currently trades at ₹18.81, while our model-based Fair Value estimate is ₹26.55 — implying the stock looks roughly 41.1% undervalued today. We read business quality at 48/100 (below-average quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, DRA generated revenue of ₹256M at a net margin of 11.3%. Revenue grew 30.8% year over year. It earns a return on equity of 8.4%. The stock trades on a trailing P/E of 7.1. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹25.26 (bear case) to ₹30.22 (bull case); at ₹18.81, the current price sits below that range. The share trades about 30% below its 52-week high and 63% above its 52-week low, currently above its 200-day average.

Key figures & financial health

Revenue (TTM) ₹256M
Revenue growth (YoY) +30.8%
Net margin 11.3%
Return on equity 8.4%
Free cash flow ₹2.8M FY2025
P/E ratio 7.1
More key figures
Operating margin 11.9%
EPS (TTM) ₹2.64
EPS growth (YoY) +13.3%

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

DRA reported revenue of ₹256M in FY2025 versus ₹2.0B in FY2021, a compound −40.3%/yr. Reported net income was ₹28.9M in FY2025, compounding −41.1%/yr from FY2021.

Revenue −40.3%/yr
FY21 ₹2.0B
FY22 ₹2.7B
FY23 ₹3.2B
FY24 ₹4.0B
FY25 ₹256M
Net income −41.1%/yr
FY21 ₹241M
FY22 ₹369M
FY23 ₹464M
FY24 ₹547M
FY25 ₹28.9M

Is DRA fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "DRA Fair Value". https://www.fairvalue-calculator.com/stock/DRA

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is DRA (DRA) undervalued?
As of Jul 5, 2026, our model estimates a fair value of ₹26.55 versus a price of ₹18.81 — about +41% (undervalued). Model-based estimate, not financial advice.
What is the fair value of DRA?
Our model-based fair value for DRA is ₹26.55 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹18.81.
What is the quality score of DRA?
DRA has a Quality Score of 48/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of DRA (DRA)?
DRA reported trailing-twelve-month revenue of about ₹256M (latest available figure, as of Jul 5, 2026).
What is the net profit margin of DRA?
The net profit margin of DRA is about 11.3%, meaning it keeps roughly 11.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.